Loading...
Market
Story
Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling
Oct 22, 2024, 07:13 PM
Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.
View original story
Similar markets
Amjevita • 25%
Wezlana • 25%
Other • 25%
None • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
Less than 10% • 25%
10-20% • 25%
21-30% • 25%
More than 30% • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Humira > Amjevita > Wezlana • 25%
Amjevita > Humira > Wezlana • 25%
Wezlana > Amjevita > Humira • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Other • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Humalog • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%